COSTA MESA, Calif.--(BUSINESS WIRE)--March 16, 2006--Synthetic Blood International, Inc. (OTCBB:SYBD) today announced that the first patient has been enrolled and treated in its eight-patient Phase II proof-of-concept study to evaluate the safety and biological effects of Oxycyte(TM) in patients with traumatic brain injury. Oxycyte is Synthetic Blood's proprietary perfluorocarbon (PFC) therapeutic oxygen carrier and blood substitute.
